Thanks for the heads-up Rich. Since this is not an area of expertise for me, my health care sector investments are almost exclusively in large cap pharma with a dividend based income stream. If Daxi is approved and gains market share you may have a 10-bagger. My take on this is that Daxi will have to be accepted as a premium, or in their terminology, a prestige solution over Botox and avoid any serious competition in that area during the first year or two. ABBV paid $63B to acquire Botox three years ago. Maybe they'll be interested in RVNC if it makes sense.
News 
Market Data 
Discover 
